MeSH term
Frequency | Condition_Probility | Antigens, CD31/analysis | 2 | 2.0 |
Cell Division/physiology | 15 | 1.0 |
Female | 205 | 0.0 |
Glycoproteins/*analysis | 2 | 2.0 |
Humans | 293 | 0.0 |
Immunohistochemistry/methods | 9 | 1.0 |
Tumor Markers, Biological/analysis | 29 | 3.0 |
Apoptosis | 8 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Cell Division | 74 | 1.0 |
Cell Nucleus/pathology | 4 | 5.0 |
Genes, p53 | 4 | 0.0 |
Neovascularization, Pathologic | 2 | 0.0 |
Ploidies | 6 | 2.0 |
Prognosis | 76 | 1.0 |
Telomerase/metabolism | 2 | 3.0 |
Cohort Studies | 3 | 0.0 |
Immunohistochemistry | 143 | 1.0 |
Ki-67 Antigen/*analysis | 22 | 32.0 |
Male | 123 | 0.0 |
Multivariate Analysis | 10 | 0.0 |
Neoplasm Staging | 30 | 1.0 |
Predictive Value of Tests | 16 | 0.0 |
Research Support, Non-U.S. Gov't | 107 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 8 | 0.0 |
Survival Analysis | 27 | 1.0 |
Time Factors | 7 | 0.0 |
Antigens, Nuclear | 45 | 30.0 |
Biopsy, Needle | 6 | 1.0 |
Breast Neoplasms/chemistry/*metabolism/pathology | 2 | 28.0 |
Immunoenzyme Techniques | 38 | 1.0 |
Nuclear Proteins/analysis/*metabolism | 2 | 18.0 |
Reproducibility of Results | 6 | 0.0 |
Adult | 142 | 0.0 |
Aged | 126 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Biopsy | 12 | 0.0 |
Comparative Study | 40 | 0.0 |
Cyclophosphamide/administration & dosage | 3 | 1.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Epirubicin/administration & dosage | 3 | 8.0 |
Middle Aged | 161 | 0.0 |
*Taxoids | 2 | 3.0 |
Tumor Markers, Biological/metabolism | 8 | 2.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 2 | 4.0 |
Axilla | 2 | 3.0 |
Disease-Free Survival | 16 | 1.0 |
Ki-67 Antigen/metabolism | 23 | 10.0 |
Lymphatic Metastasis | 12 | 1.0 |
Neoplasm Invasiveness | 14 | 1.0 |
Nuclear Proteins/metabolism | 11 | 1.0 |
Prospective Studies | 5 | 0.0 |
S Phase | 4 | 1.0 |
Survival Rate | 27 | 1.0 |
Cell Division/drug effects | 2 | 0.0 |
Nuclear Proteins/analysis | 18 | 10.0 |
Adolescent | 37 | 0.0 |
Ki-67 Antigen | 40 | 18.0 |
Diagnosis, Differential | 18 | 0.0 |
Tumor Markers, Biological/*analysis | 31 | 3.0 |
English Abstract | 19 | 0.0 |
Nuclear Proteins/*metabolism | 13 | 1.0 |
Tumor Markers, Biological/*metabolism | 14 | 3.0 |
*Muscle Proteins | 2 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Cell Movement/physiology | 2 | 0.0 |
Retrospective Studies | 30 | 0.0 |
Salivary Gland Neoplasms/*pathology | 2 | 18.0 |
Chromosome Deletion | 2 | 0.0 |
DNA, Neoplasm/analysis | 5 | 0.0 |
Disease Progression | 10 | 0.0 |
Follow-Up Studies | 24 | 0.0 |
Immunophenotyping | 8 | 0.0 |
Double-Blind Method | 2 | 0.0 |
*Estrogen Replacement Therapy | 2 | 1.0 |
*Ploidies | 3 | 4.0 |
Child | 26 | 0.0 |
Child, Preschool | 19 | 0.0 |
Gene Expression | 4 | 0.0 |
Genes, p53/genetics | 2 | 0.0 |
Hyperplasia | 6 | 1.0 |
Infant | 13 | 0.0 |
Ki-67 Antigen/analysis | 28 | 10.0 |
Loss of Heterozygosity | 2 | 0.0 |
Protein p53/analysis | 18 | 6.0 |
Apoptosis/*physiology | 2 | 0.0 |
Biological Markers | 2 | 0.0 |
Combined Modality Therapy | 7 | 0.0 |
Aged, 80 and over | 68 | 0.0 |
Apoptosis/physiology | 2 | 0.0 |
In Situ Nick-End Labeling | 6 | 1.0 |
Ki-67 Antigen/biosynthesis | 4 | 5.0 |
Protein p53/biosynthesis | 3 | 2.0 |
*Apoptosis | 11 | 0.0 |
*Cell Cycle | 2 | 0.0 |
*Cell Division | 7 | 4.0 |
DNA, Neoplasm/genetics | 5 | 0.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Translocation, Genetic | 2 | 0.0 |
Adenoma/*metabolism/pathology | 2 | 5.0 |
Proliferating Cell Nuclear Antigen/analysis | 14 | 5.0 |
Adenoma/metabolism/*pathology | 2 | 15.0 |
Keratin/analysis | 5 | 2.0 |
Chi-Square Distribution | 2 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Sensitivity and Specificity | 10 | 0.0 |
Necrosis | 3 | 0.0 |
Neoplasm Proteins/*analysis | 25 | 7.0 |
Receptor, erbB-2/analysis | 10 | 10.0 |
Receptors, Estrogen/analysis | 10 | 2.0 |
Receptors, Progesterone/analysis | 10 | 4.0 |
Breast Neoplasms/*chemistry | 3 | 4.0 |
Cathepsin D/analysis | 4 | 11.0 |
DNA-Binding Proteins/*analysis | 2 | 3.0 |
Flow Cytometry | 6 | 0.0 |
Mitotic Index | 14 | 8.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 8 | 4.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
Neoplasm Proteins/*metabolism | 8 | 1.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Antibodies, Monoclonal | 19 | 0.0 |
Neoplasm Proteins/analysis | 11 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 4 | 0.0 |
Receptors, Estrogen/metabolism | 6 | 2.0 |
Tamoxifen/*therapeutic use | 2 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Cyclin D1/*analysis | 2 | 18.0 |
Cyclins/*analysis | 2 | 5.0 |
Treatment Outcome | 8 | 0.0 |
Biological Markers/analysis | 12 | 1.0 |
Breast Neoplasms/*enzymology/pathology | 2 | 6.0 |
Tumor Cells, Cultured | 6 | 0.0 |
Carcinoma, Ductal, Breast/chemistry | 2 | 25.0 |
Proto-Oncogene Proteins/analysis | 4 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/*analysis | 3 | 3.0 |
Receptor, Epidermal Growth Factor/analysis | 4 | 2.0 |
Retinoblastoma Protein/analysis | 2 | 5.0 |
Fatal Outcome | 3 | 0.0 |
Neoplasm Invasiveness/*pathology | 2 | 7.0 |
Chronic Disease | 2 | 0.0 |
Liver/metabolism | 2 | 0.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Proliferating Cell Nuclear Antigen/biosynthesis | 2 | 4.0 |
Protein p53/*biosynthesis | 5 | 4.0 |
Precancerous Conditions/*pathology | 2 | 7.0 |
Probability | 2 | 0.0 |
Protein p53/*analysis | 11 | 5.0 |
Receptor, erbB-2/*analysis | 4 | 4.0 |
Bladder Neoplasms/*metabolism/pathology | 3 | 9.0 |
Nuclear Proteins/biosynthesis | 2 | 4.0 |
Proliferating Cell Nuclear Antigen/*biosynthesis | 2 | 3.0 |
Receptor, erbB-2/*biosynthesis | 2 | 4.0 |
Tumor Markers, Biological | 5 | 1.0 |
Carcinoembryonic Antigen/analysis | 2 | 1.0 |
Bladder Neoplasms/metabolism | 2 | 20.0 |
Evaluation Studies | 4 | 0.0 |
Fixatives | 2 | 2.0 |
Image Processing, Computer-Assisted | 10 | 2.0 |
Immunohistochemistry/*methods | 4 | 4.0 |
Protein p53/*metabolism | 10 | 1.0 |
Lymph Nodes/pathology | 5 | 1.0 |
Endometrial Hyperplasia/metabolism | 2 | 40.0 |
Endometrial Neoplasms/*metabolism/pathology | 2 | 6.0 |
Endometrium/metabolism | 2 | 3.0 |
Metallothionein/*metabolism | 2 | 20.0 |
Breast Neoplasms/metabolism/*pathology | 4 | 4.0 |
Neoplasm Metastasis | 4 | 0.0 |
Risk Factors | 2 | 0.0 |
Animals | 8 | 0.0 |
Cell Count | 4 | 0.0 |
Cell Division/*physiology | 4 | 2.0 |
Cell Transformation, Neoplastic/*pathology | 2 | 7.0 |
Mice | 3 | 0.0 |
Antigens, Neoplasm/metabolism | 2 | 2.0 |
*Genes, p53 | 3 | 0.0 |
Ki-67 Antigen/*metabolism | 8 | 17.0 |
*Cell Cycle Proteins | 2 | 0.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Pituitary Gland/pathology | 3 | 13.0 |
Nuclear Proteins/*analysis | 22 | 12.0 |
Proto-Oncogene Proteins/*analysis | 2 | 1.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 3 | 3.0 |
Treatment Failure | 3 | 1.0 |
Tumor Markers, Biological/*genetics | 3 | 2.0 |
Meningeal Neoplasms/chemistry/*pathology/surgery | 2 | 50.0 |
Meningioma/chemistry/*pathology/surgery | 2 | 100.0 |
Analysis of Variance | 6 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Cervical Intraepithelial Neoplasia/*diagnosis/metabolism | 2 | 100.0 |
Proliferating Cell Nuclear Antigen/metabolism | 5 | 2.0 |
Protein p53/metabolism | 8 | 1.0 |
Cell Nucleus/chemistry | 3 | 1.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Biopsy/methods | 2 | 4.0 |
Phosphopyruvate Hydratase/analysis | 2 | 2.0 |
DNA/analysis | 2 | 0.0 |
Immunochemistry | 3 | 1.0 |
In Situ Hybridization | 6 | 0.0 |
Microscopy, Electron | 5 | 0.0 |
Antigens, CD34/analysis | 2 | 0.0 |
Vimentin/analysis | 2 | 0.0 |
von Willebrand Factor/analysis | 2 | 0.0 |
*DNA Topoisomerases, Type II, Eukaryotic | 2 | 10.0 |
Nuclear Proteins/*biosynthesis | 2 | 4.0 |
Tumor Markers, Biological/*biosynthesis | 2 | 2.0 |
Adenoma/*pathology/surgery | 2 | 50.0 |
Breast Neoplasms/*pathology | 5 | 2.0 |
Neoplasm Staging/*methods | 2 | 5.0 |
*Mitotic Index | 2 | 20.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Lymph Nodes/*pathology | 2 | 2.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Receptors, Progesterone/metabolism | 5 | 2.0 |
Antibodies, Monoclonal/*diagnostic use | 8 | 3.0 |
Chemotherapy, Adjuvant | 3 | 1.0 |
Blotting, Western | 3 | 0.0 |
Enzyme Inhibitors/*metabolism | 2 | 2.0 |
Antibodies, Monoclonal/immunology | 6 | 0.0 |
Genes, p53/*genetics | 3 | 0.0 |
Nucleolus Organizer Region/*pathology | 2 | 15.0 |
Biological Markers/*analysis | 2 | 1.0 |
Vascular Endothelial Growth Factor A | 3 | 0.0 |
Vascular Endothelial Growth Factors | 3 | 0.0 |
Brain/pathology | 2 | 0.0 |
Organ Size | 2 | 1.0 |
Cell Differentiation | 7 | 0.0 |
Neoplasm Recurrence, Local | 5 | 1.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
Age Factors | 2 | 0.0 |
Cyclins/*metabolism | 6 | 2.0 |
Sex Factors | 2 | 0.0 |
Endothelium, Vascular/pathology | 3 | 2.0 |
Stromal Cells/pathology | 3 | 5.0 |
Acute Disease | 2 | 0.0 |
Tumor Markers, Biological/biosynthesis | 2 | 5.0 |
Cervix Neoplasms/*metabolism | 2 | 6.0 |
*Monomeric GTP-Binding Proteins | 2 | 4.0 |
*Nucleoside-Diphosphate Kinase | 2 | 3.0 |
Proportional Hazards Models | 2 | 0.0 |
Staining and Labeling | 3 | 0.0 |
Autoantigens/metabolism | 3 | 7.0 |
Carcinoma, Squamous Cell/*pathology | 2 | 2.0 |
Cyclin A/*metabolism | 2 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 4 | 1.0 |
Receptor, erbB-2/metabolism | 3 | 1.0 |
S Phase/physiology | 2 | 2.0 |
Tissue Distribution | 4 | 0.0 |
Breast Neoplasms/*chemistry/*pathology | 2 | 20.0 |
Cell Death | 2 | 0.0 |
Cyclins/analysis | 2 | 4.0 |
Mitosis | 4 | 0.0 |
Postmenopause | 2 | 1.0 |
Tomography, X-Ray Computed | 5 | 0.0 |
Antibodies, Neoplasm/analysis | 2 | 7.0 |
Glial Fibrillary Acidic Protein/analysis | 2 | 1.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Antigens, CD44/*metabolism | 2 | 1.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
Pregnancy | 5 | 0.0 |
Cell Cycle Proteins/*analysis | 2 | 11.0 |
Antibodies, Monoclonal/diagnostic use | 8 | 0.0 |
Adenocarcinoma/metabolism/*pathology | 2 | 3.0 |
Nuclear Proteins/*analysis/immunology | 3 | 30.0 |
Paraffin Embedding | 7 | 2.0 |
Prevalence | 2 | 0.0 |
*DNA Fragmentation | 2 | 10.0 |
Cell Cycle | 5 | 0.0 |
Cyclin D1/metabolism | 2 | 1.0 |
Antigens, Neoplasm/*analysis | 3 | 0.0 |
Receptors, Estrogen/*analysis | 3 | 1.0 |
CA-15-3 Antigen/analysis | 3 | 4.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Automation | 2 | 3.0 |
Epithelium/chemistry | 2 | 1.0 |
S Phase/*physiology | 2 | 4.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Lymphoma, Non-Hodgkin/*pathology | 2 | 14.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
Ovarian Neoplasms/*pathology | 2 | 3.0 |
*Immunohistochemistry | 2 | 2.0 |
Skin Neoplasms/*pathology | 2 | 2.0 |
Mutation | 2 | 0.0 |
Autoantigens/analysis | 2 | 6.0 |
Carcinoma, Ductal, Breast/*pathology | 2 | 22.0 |
Recurrence | 2 | 0.0 |
Brain Neoplasms/chemistry/*pathology | 2 | 28.0 |
Carcinoma, Transitional Cell/*pathology | 2 | 28.0 |
Kidney Neoplasms/*pathology | 2 | 6.0 |
Neoplasm Proteins | 2 | 6.0 |
Nuclear Proteins | 2 | 4.0 |
Ki-67 Antigen/analysis/biosynthesis | 2 | 40.0 |
Adenoma/*pathology | 2 | 9.0 |
Antigens, Neoplasm/analysis | 3 | 0.0 |
Neoplasm Proteins/*analysis/immunology | 2 | 11.0 |
Proliferating Cell Nuclear Antigen/*analysis | 4 | 2.0 |
Ki-67 Antigen/*biosynthesis | 4 | 15.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 2 | 1.0 |
Adenocarcinoma/immunology/*pathology | 2 | 13.0 |
Meninges/pathology | 2 | 20.0 |
Neoplasm Proteins/immunology | 2 | 5.0 |
Nuclear Proteins/immunology | 2 | 6.0 |
Proliferating Cell Nuclear Antigen | 4 | 1.0 |
*Hematopoiesis | 2 | 1.0 |
S100 Proteins/metabolism | 2 | 1.0 |
Breast Neoplasms/*drug therapy/*pathology | 2 | 25.0 |
Transcription Factors/analysis | 2 | 2.0 |
